Valproic acid treatment results in increased accumulation of prion proteins

Annals of Neurology

Volumn 52, Issue 4, 2002, Pages 416-420

  Shaked, Gideon M ^a   Engelstein, Roni ^a   Avraham, Inbal ^a   Rosenmann, Hannah ^a   Gabizon, Ruth ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PRION PROTEIN; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; HAMSTER; INCUBATION TIME; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICONVULSANTS; CRICETINAE; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; NEUROBLASTOMA; PRIONS; PRPC PROTEINS; PRPSC PROTEINS; SCRAPIE; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 0036791879     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10298     Document Type: Article

References (31)

1. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998;95: 13363-13383.
2. Brown DR, Qin K, Herms JW, et al. The cellular prion protein binds copper in vivo. Nature 1997;390:684-687.
3. Hornshaw MP, McDermott JR, Candy JM, Lakey JH. Copper binding to the N-terminal tandem repeat region of mammalian and avian prion protein: structural studies using synthetic peptides. Biochem Biophys Res Commun 1995;214:993-999.
4. Baldwin MA, Cohen FE, Prusiner SB. Prion protein isoforms, a convergence of biological and structural investigations. J Biol Chem 1995;270:19197-19200.
5. Butler DA, Scott, MR, Bockman JM, et al. Scrapie-infected murine neuroblastoma cells produce protease-resistant prion proteins. J Virol 1988;62:1558-1564.
6. Caughey B, Race RE, Ernst D, et al. Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol 1989;63:175-181.
7. Borchelt DR, Scott M, Taraboulos A, et al. Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J Cell Biol 1990;110:743-752.
8. Naslavsky N, Stein R, Yanai A, et al. Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform. J Biol Chem 1997;272:6324-6331.
9. Naslavsky N, Shmeeda H, Friedlander G, et al. Sphingolipid depletion increases formation of the scrapie prion protein in neuroblastoma cells infected with prions. J Biol Chem 1999; 274:20763-20771.
10. Chapman CJ. Drugs and genes: therapeutic implications. Drugs 1977;14:120-127.
11. Farriello R, Smith MC. Valproate, mechanisms of action in antiepileptic drugs. In: Levy R, Meldrum RMB, Penry JK, Dreifuss FE, eds. New York: Raven Press, 1989:567-576.
12. Loscher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem Pharmacol 1981;30:1364-1366.
13. Godin Y, Heiner L, Mark J, Mandel P. Effects of DI-npropylacetate, and anticonvulsive compound, on GABA metabolism. J Neurochem 1969;16:869-873.
14. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36:S2-S12.
15. Perlman BJ, Goldstein DB. Membrane-disordering potency and anticonvulsant action of valproic acid and other short-chain fatty acids. Mol Pharmacol 1984;26:83-89.
16. Lyon RC, Goldstein DB. The comparative effects of sodium valproate, sodium octanoate, and sodium valerate on spin labeled synaptosomal plasma membranes from mouse brain. Fed Proc 1980;39:1100.
17. Rumbach L, Mutet C, Cremel G, et al. Effects of sodium valproate on mitochondrial membranes: electron paramagnetic resonance and transmembrane protein movement studies. Mol Pharmacol 1986;30:270-273.
18. Seeman P. The membrane actions of anesthetics and tranquilizers. Pharmacol Rev 1972;24:583-655.
19. Chapman A, Keane PE, Meldrum BS, et al. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982;19: 315-359.
20. Loscher W, Nau H. Valproic acid: metabolite concentrations in plasma and brain, anticonvulsant activity, and effects on GABA metabolism during subacute treatment in mice. Arch Int Pharmacodyn Ther 1982;257:20-31.
21. Cloyd JC, Fischer JH, Kriel RL, Kraus DM. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther 1993;53:22-29.
22. Qume M, Whitton PS, Fowler LJ. The effect of chronic treatment with the GABA transaminase inhibitors gamma-vinyl-GABA and ethanolamine-O-sulphate on the in vivo release of GABA from rat hippocampus. J Neurochem 1995;64: 2256-2261.
23. Shaked GM, Fridlander G, Meiner Z, et al. Protease-resistant and detergent-insoluble prion protein is not necessarily associated with prion infectivity. J Biol Chem 1999;274:17981-17986.
24. Caspi S, Halimi, M, Yanai, et al. The anti-prion activity of Congo red. Putative mechanism. J Biol Chem 1998;273: 3484-3489.
25. Yanai A, Meiner Z, Gahali I, et al. Subcellular trafficking abnormalities of a prion protein with a disrupted disulfide loop. FEBS Lett 1999;460:11-16.
26. Taraboulos A, Serban D, Prusiner SB. Scrapie prion proteins accumulate in the cytoplasm of persistently infected cultured cells. J Cell Biol 1990;110:2117-2132.
27. Loscher W. Anticonvulsant and biochemical effects of inhibitors of GABA aminotransferase and valproic acid during subchronic treatment in mice. Biochem Pharmacol 1982;31: 837-842.
28. Ingrosso L, Ladogana A, Pocchiari M. Congo red prolongs the incubation period in scrapie-infected hamsters. J Virol 1995;69: 506-508.
29. Collinge J, et al. Prion protein is necessary for normal synaptic function. Nature 1994;370:295-297.
30. Evans WE, Schentag JJ, Jusko WJ. Applied pharmacokinetics. Vancouver: Applied Therapeutics, 1992.
31. Yukawa E, To H, Ohdo S, et al. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol 1997;37:1160-1167.